HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator.

Abstract
Glucokinase activators (GKAs), such as AZD1656, are designed as antihyperglycemic agents for diabetics and can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies. Genetically modified heterozygous GK knockout (gkdel/wt) mice are less susceptible to severe GKA-induced hypoglycemia than wild-type mice due to their elevated baseline glucose levels. In this study, the gkdel/wt mouse was used as an alternative rodent strain for embryofetal development studies with AZD1656. Heterozygous global knockout gkdel/wt females were dosed with 20, 50, or 130 mg/kg/day of AZD1656 or vehicle for a minimum of 14 consecutive days before mating with wild-type males and throughout organogenesis. Maternal effects were confined to slightly reduced food consumption, reduced body weight gain, and the pharmacologic effect of decreased plasma glucose. Fetuses were genotyped. Fetal weights at the high dose were slightly reduced but there was no effect on fetal survival. There were two specificmajormalformations, omphalocele and right-sided aortic arch, with increased fetal incidence in mid- and high-dose fetuses (e.g., omphalocele fetal incidence of 0.6, 0.7, 4.6, and 2% across the dose groups) plus increased incidences of minor abnormalities and variants indicative of either delayed or disturbed development. Fetal weight and abnormalities were unaffected by fetal genotype. The fetal effects are considered hypoglycemia related. There was no effect on embryofetal survival in the gkdel/wt mouse at AZD1656 exposures, which were 70× higher than those causing 75% fetal death in rabbits. This illustrates the value of genetically modified animals in unraveling target versus chemistry-related effects.
AuthorsTerri Mitchard, Jane Stewart
JournalBirth defects research. Part B, Developmental and reproductive toxicology (Birth Defects Res B Dev Reprod Toxicol) Vol. 101 Issue 2 Pg. 152-61 (Apr 2014) ISSN: 1542-9741 [Electronic] United States
PMID24753370 (Publication Type: Journal Article)
Chemical References
  • AZD1656
  • Azetidines
  • Pyrazines
  • Pyridines
  • glucokinase activator compound 50
Topics
  • Animals
  • Area Under Curve
  • Azetidines (pharmacology)
  • Dose-Response Relationship, Drug
  • Embryonic Development (drug effects)
  • Female
  • Fetus (drug effects, embryology, pathology)
  • Heterozygote
  • Male
  • Maternal Exposure
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Pyrazines (pharmacology)
  • Pyridines (pharmacology)
  • Rabbits

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: